You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《盈利預喜》藥明合聯(02268.HK)料去年淨利潤按年增長逾八成
阿思達克 02-01 07:59
藥明合聯(02268.HK)發盈喜,預期去年銷售收入按年增長超過100%;淨利潤增長超過80%;經調整淨利潤增長超過100%。 公司認為,有關預期增長主要得益於抗體藥物偶聯物(ADC)行業的持續活躍發展,以及公司在贏得項目方面的獨特競爭優勢。 此外,公司於去年11月上市後獲得多個PPQ項目(生產工藝驗證項目,通常在商業生產規模下進行交付執行),並與多家專注於ADC開發的創新生物科技公司簽署技術合作項目。公司對業務前景充滿信心,並將一如既往地專注於業務發展,幫助客戶開發和推進各項目生物偶聯項目。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account